Konerman Monica A, Fritze Danielle, Weinberg Richard L, Sonnenday Christopher J, Sharma Pratima
1 Division of Gastroenterology and Hepatology. 2 Department of Surgery. 3 Division of Cardiology, University of Michigan Health System, Ann Arbor, Michigan.
Transplantation. 2017 Jul;101(7):1645-1657. doi: 10.1097/TP.0000000000001710.
Cardiovascular events represent a major source of morbidity and mortality after liver transplantation and will likely increase given the aging population and nonalcoholic fatty liver disease as a leading indication for transplant. The optimal cardiovascular risk stratification approach in this evolving patient population remains unclear. The aims of this systematic review are to: (1) refine the definition, (2) characterize the incidence, and (3) identify risk factors for cardiovascular events post-liver transplantation. Additionally, we evaluated performance characteristics of different cardiac testing modalities.
MEDLINE via PubMed, EMBASE, Web of Science, and Scopus were searched for studies published between 2002 and 2016 (model of end-stage liver disease era). Two authors independently reviewed articles to select eligible studies and performed data abstraction.
Twenty-nine studies representing 57 493 patients from 26 unique cohorts were included. Definitions of cardiovascular outcomes were highly inconsistent. Incidence rates were widely variable: 1% to 41% for outcomes of 6 months or shorter and 0% to 31% for outcomes longer than 6 months. Multivariate analyses demonstrated that older age and history of cardiac disease were the most consistent predictors of cardiovascular events posttransplant (significant in 8/23 and 7/22, studies, respectively). Predictive capacity of various cardiac imaging modalities was also discrepant.
The true incidence of cardiovascular outcomes post-liver transplant remains unknown in large part due to lack of consensus regarding outcome definition. Overall, poor data quality and gaps in knowledge limit the ability to clearly identify predictors of outcomes, but existing data support a more aggressive risk stratification protocol for patients of advanced age and/or with preexisting cardiac disease.
心血管事件是肝移植后发病和死亡的主要原因,鉴于人口老龄化以及非酒精性脂肪性肝病成为肝移植的主要适应症,心血管事件可能会增加。在这一不断变化的患者群体中,最佳的心血管风险分层方法仍不明确。本系统评价的目的是:(1)完善定义;(2)描述发病率;(3)确定肝移植后心血管事件的危险因素。此外,我们还评估了不同心脏检查方式的性能特征。
通过PubMed、EMBASE、科学网和Scopus检索MEDLINE中2002年至2016年(终末期肝病模型时代)发表的研究。两位作者独立审查文章以选择符合条件的研究并进行数据提取。
纳入了来自26个独特队列的29项研究,共57493例患者。心血管结局的定义高度不一致。发病率差异很大:6个月或更短时间的结局为1%至41%,超过6个月的结局为0%至31%。多变量分析表明,年龄较大和有心脏病史是移植后心血管事件最一致的预测因素(分别在8/23和7/22的研究中有显著意义)。各种心脏成像方式的预测能力也存在差异。
肝移植后心血管结局的真实发病率在很大程度上仍不清楚,这主要是由于对结局定义缺乏共识。总体而言,数据质量差和知识空白限制了明确识别结局预测因素的能力,但现有数据支持对高龄和/或已有心脏病的患者采用更积极的风险分层方案。